Evidence Level:Sensitive: D – Preclinical
New
Title:
SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma
Excerpt:...CD48 is a highly expressed new multiple myeloma target and the novel glucuronide-MMAE ADC SGN-CD48A shows potent antitumor activity against cell line models of MM.
DOI:https://doi.org/10.1182/blood.V128.22.4470.4470